- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04630704
Evaluating A Non-Invasive Tissue Perfusion Monitor
13. november 2020 oppdatert av: Pedra Technology, PTE LTD
A Feasibility Study Evaluating A Non-Invasive Tissue Perfusion Monitor Utilising Diffuse Speckle Contrast Analysis
The Pedra perfusion system will be used to assess changes in perfusion in response to physiological stimuli.
It will be compared to other standard diagnostics.
Studieoversikt
Detaljert beskrivelse
The Pedra perfusion system measures microvascular flow through diffuse speckle contrast analysis.
It will be used to assess changes in perfusion in response to a number of physiological stimuli.
It will be compared to other standard diagnostics including ankle-brachial index, toe-brachial index and transcutaneous oxygen measurement.
Measurements will be undertaken in non-vascular patients as well as those with chronic limb threatening ischaemia.
Studietype
Observasjonsmessig
Registrering (Forventet)
50
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
40 år til 90 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Patients with palpable pulses and patients with chronic limb threatening ischaemia
Beskrivelse
Inclusion Criteria:
CLTI cohort
- At least 40 years old
- Each patient will have documented arterial occlusive disease within 6 weeks of enrolment as determined by an ankle-brachial index (ABI) < 0.7 but not greater than 1.2, toe-brachial index (TBI) <0.5, skin perfusion pressure (SPP) less than 30mmHg, OR Transcutaneous oxygen measurement (TCOM) < 40mmHg in diabetics and <30mmHg in non-diabetics.
- The presence of skin breakdown compatible which with an underlying ischemic element (previous minor amputation for gangrene also included) that the Principle Investigator (PI) deems appropriate for the study.
- Subject has read, understood and signed approved consent, and is willing to participate and comply with the study procedures and requirements.
Non-vascular group
- At least 40 years old
- Each patient will have documented palpable foot pulses
- 21 patients will be free of lower limb oedema and 6 patients will have moderate oedema present
- Subject has read, understood and signed approved consent, and is willing to participate and comply with the study procedures and requirements.
Exclusion Criteria:
CLTI Cohort
- Subject on an investigational drug or therapeutic device within 30 days of the study visit, which in the view of the PI may compromise the study results.
- Presence of a condition that PI considers will compromise the subject's ability to participate in the study.
- Age <40 or >90
- Inability to straight leg raise to 30 degrees or tolerate calf cuff occlusion.
- Has smoked cigarettes/e-cigarettes on the day of testing.
- Has taken caffeine drinks on the day of testing
- In the last 3 hours the subject has exercised beyond normal daily walking.
- Inability to have TBI measured (e.g. absence of toe)
- Signs of active infection causing localised inflammation on the plantar or dorsal surfaces of the foot
- Pathological skin conditions that may impair the ability of the adhesive sensor pads to adhere.
Non-vascular Cohort
- Subject on an investigational drug or therapeutic device within 30 days of the study visit, which in the view of the PI may compromise the study results.
- Presence of a condition that PI considers will compromise the subject's ability to participate in the study.
- Age <40 or >90
- Inability to straight leg raise to 30 degrees or tolerate calf cuff occlusion.
- Has smoked cigarettes/e-cigarettes on the day of testing.
- Has taken caffeine drinks on the day of testing
- In the last 3 hours the subject has exercised beyond normal daily walking.
- Inability to have TBI measured (e.g. absence of toe)
- Signs of active infection causing localised inflammation on the plantar or dorsal surfaces of the foot
- Pathological skin conditions that may impair the ability of the adhesive sensor pads to adhere.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Case-Control
- Tidsperspektiver: Potensielle
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Non vascular repeatibility
This cohort of patients with palpable pulses will be used to test inter- and intra- observer variability for the Pedra system
|
Diffuse speckle contrast analysis perfusion system
|
|
Non vascular physiology
This cohort of patients with palpable pulses will assess the ability of Pedra to detect perfusion changes in response to physiologic stimuli.
|
Diffuse speckle contrast analysis perfusion system
|
|
CLTI physiology
This cohort of patients with CLTI will assess the ability of Pedra to detect perfusion changes in response to physiologic stimuli.
|
Diffuse speckle contrast analysis perfusion system
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The Blood Perfusion Index (unitless number) delta in response to reduction in arterial inflow pressure
Tidsramme: Intra-procedure
|
The range of change in the Blood Perfusion Index (unitless) in response to physiologic changes in arterial perfusion, in patients with healthy circulation and those with compromised arterial circulation
|
Intra-procedure
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Reliability of Blood Perfusion Index measurement will be assessed on repeated measures by determination of the correlation coefficient
Tidsramme: intra-procedure
|
The reliability of measurement of the Blood Perfusion Index will be measured and compared to standard diagnostics
|
intra-procedure
|
|
Repeatability of Blood Perfusion Index measurement will be assessed on repeated measures by determination of the correlation coefficient
Tidsramme: intra-procedure
|
The repeatability of measurement of the Blood Perfusion Index will be measured and compared to standard diagnostics
|
intra-procedure
|
|
Sensitivity of Pedra to detect differences in the Blood Perfusion Index between patient subsets
Tidsramme: Intra-procedure
|
Use of a ROC curve to assess the ability of the Blood Perfusion Index to differentiate between those with healthy circulation and those with arterial disease
|
Intra-procedure
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Forventet)
7. desember 2020
Primær fullføring (Forventet)
1. april 2021
Studiet fullført (Forventet)
1. juli 2021
Datoer for studieregistrering
Først innsendt
5. november 2020
Først innsendt som oppfylte QC-kriteriene
13. november 2020
Først lagt ut (Faktiske)
16. november 2020
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
16. november 2020
Siste oppdatering sendt inn som oppfylte QC-kriteriene
13. november 2020
Sist bekreftet
1. november 2020
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- Pedra-001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Nei
IPD-planbeskrivelse
No plan to share data
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Ja
produkt produsert i og eksportert fra USA
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .